The Latest Cardiac and Vascular News
PDUFA Date Extension to End of December 2019 Expected Management to Host Conference Call Today at 7:00 p.m. ET BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 08, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that it received notice today from the […]
BEDMINSTER, N.J., and DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares (“ADSs”), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of […]
BEDMINSTER, N.J. and DUBLIN, Ireland, July 17, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of $400,000,000 of its American Depositary Shares pursuant to a shelf registration. All of the shares in the proposed offering are to be sold […]
Record Revenue Achieved in 1H19 Primarily Due to Increased Demand for Vascepa Guidance for Total 2019 Revenue Increased to a Range of $380 to $420 Million from $350 Million Following Unaudited Second Quarter Results Estimated Between $97 and $101 Million, or Between $170 and $174 Million for the First Half […]
BEDMINSTER, N.J. and DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, president and chief executive officer of Amarin, has been named EY’s Entrepreneur of The Year […]
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking an expanded indication for its […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with […]
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 23, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced that new data showing the reduction in total major adverse cardiovascular (i.e., ischemic) events shown in the landmark REDUCE-IT™ cardiovascular outcomes trial has been accepted for […]
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 02, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a company update at […]
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to participate in a fireside chat regarding […]
